We have been following the IPRs filed by Mylan against Genentech’s U.S. Patent No. 6,407,213, which relates to humanized antibody polypeptides and methods for their preparation and use.
On Tuesday, March 7th, the parties filed motions in IPR2016-0193 and IPR2016-01694 asking the Board to terminate the IPRs due to settlement. No institution decision had as yet been made in either petition.
For more biosimilar news, stay tuned to Big Molecule Watch.
